Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The ArtixASCEND Study, officially titled ‘The Artix All-in-one Solution for Complete thrombEctomy With eNDovascular Approach,’ aims to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions. This post-market, prospective, multicenter, single-arm study holds significant potential for improving treatment outcomes in vascular health.
Intervention/Treatment: The study tests the Artix Thrombectomy System, a device designed for the non-surgical removal of arterial emboli and thrombi in the lower extremities, offering a potentially safer and more effective treatment option.
Study Design: This interventional study follows a single-group model without masking, focusing on treatment as the primary purpose. Participants will receive the Artix Thrombectomy System intervention, with outcomes measured to assess its safety and effectiveness.
Study Timeline: The study is not yet recruiting, with an estimated start date of November 1, 2025. The primary completion and estimated completion dates are yet to be announced, but the last update was submitted on August 20, 2025, indicating ongoing preparations.
Market Implications: The successful execution and positive outcomes of the ArtixASCEND Study could enhance Inari Medical’s market position, potentially boosting its stock performance. This development may also influence investor sentiment positively, especially in the competitive landscape of vascular treatment technologies.
Closing Sentence: The ArtixASCEND Study is ongoing, with further details available on the ClinicalTrials portal.